Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
6 evidence topics · 3 sources
Reduction of pMARCKS and pPKC delta in tumor biopsies and peripheral blood mononuclear cells in the first-in-human study
“LXS196 reduced pMARCKS and phosphorylated PKC delta (pPKC delta), suggesting target engagement in on-treatment tumour biopsies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reduction in pPKC delta in PBMCs was observed within 6 h post-dose at all dose levels (Fig. 2a, b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (range) reduction in percentage change from baseline to C1D15 (normalised ratio) for pPKC delta and pMARCKS was −68.1 (−91.4, −28.6) and −39.7 (−89.7, 199), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No association between the extent of pMARCKS or pPKC delta suppression and dose group in the first-in-human study
“A decrease in pMARCKS/MARCKS was observed by C1D15 in patient tumour samples; however, no clear associations were detected between the extent of pMARCKS suppression and LXS196 treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with this, a decrease in pPKCd was observed by C1D15, but no correlation was seen between the extent of suppression and the LXS196 treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The decrease in pPKCd was also observed in PBMCs, which are not expected to carry mutations in the GNAQ/GNA11 pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
RasGRP3 and DUSP6 expression in the first-in-human study
“RasGRP3 was decreased in some patients receiving LXS196 both QD and BID (Supplementary Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Levels of RasGRP3 at screening and after treatment also correlate with the best percent change in tumour volume from baseline (Supplementary Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MAPK pathway activity as measured by DUSP6 expression showed a trend towards suppression in the PR group (Supplementary Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory analysis of RasGRP3 reveals a potential biomarker for predicting efficacy and evidence of a transcriptional regulatory feedback on RasGRP3 by PKC inhibition and warrants further investigation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical tumor regression in the 92.1 uveal melanoma xenograft model
“When assessed in the 92.1 human UM mouse xenograft model, LXS196 dosed as a single agent leads to tumour regression at doses below its maximum tolerated dose (MTD), in contrast to AEB071, which achieves only stasis in this model” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote